Compare Main Street Capital Corporation (MAIN) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Novavax Inc — how do they compare? Main Street Capital Corporation trades at $58.84 (market cap $5.47B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Main Street Capital Corporation is far larger — about 4.2× Novavax Inc's market cap, and Main Street Capital Corporation pays a 5.43% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MAIN | NVAX | |
|---|---|---|
Market Cap | $5.47B | $1.30B |
Sector | Financials | Health |
52-Week High | $67.54 | $11.19 |
52-Week Low | $49.63 | $6.22 |
Dividend Yield | 5.43% | — |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $58.94, up 3.79% with strong technical momentum. The stock shows bullish technical signals with support at $57 and resistance at $60. Recent Q2 2026 earnings beat expectations at $0.97 per share, though Q1 missed. The company maintains an 80.77% net income margin with consistent dividend payments, positioning it as a reliable income stock. Revenue trends show slight moderation from 2024's peak but remain above 2022-2023 levels.
Outlook remains positive given MAIN's strong profitability and dividend consistency, though near-term risks include expense pressures impacting earnings coverage and broader market volatility. Analyst consensus leans cautious with 78.57% hold ratings, suggesting limited upside from current levels despite the stock's technical strength and income appeal.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
